2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-153835A
    Pegnivacogin sodium
    		Inhibitor
    Pegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin sodium
  • HY-B0597R
    Fondaparinux sodium (Standard)
    		Inhibitor
    Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
    Fondaparinux sodium (Standard)
  • HY-P3009D
    Rat Factor Xa
    Rat Factor Xa is prepared by activating purified Rat Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.
    Rat Factor Xa
  • HY-153817
    FXIa-IN-13
    		Inhibitor
    FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro.
    FXIa-IN-13
  • HY-10758
    FXa-IN-1
    		Inhibitor
    FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders.
    FXa-IN-1
  • HY-168712
    FXIa-IN-15
    		Inhibitor
    FXIa-IN-15 (Compound (S)-10h) is an inhibitor for Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC50 of 0.38 nM and 59.2 nM. FXIa-IN-15 exhibits anticoagulant efficacy, that extends 50% activated partial thromboplastin time (aPTT) with EC1.5X of 0.55 μM.
    FXIa-IN-15
  • HY-10756
    BMS-740808
    		Inhibitor
    BMS-740808 is a potent, selective and orally active factor Xa inhibitor with a Ki of 30 pM. BMS-740808 shows >1000-fold for factor Xa than other proteases.
    BMS-740808
  • HY-P3009C
    Rabbit Factor Xa
    Rabbit Factor Xa is prepared by activating purified Rabbit Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.
    Rabbit Factor Xa
  • HY-123356
    EMD-503982
    		Inhibitor
    EMD-503982 is an orally available FXa inhibitor.
    EMD-503982
  • HY-150682
    FXIa-IN-9
    		Inhibitor
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism.
    FXIa-IN-9
  • HY-W145053
    ChloraMine-T hydrate
    		Inhibitor
    ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) is a common reagent in various synthetic processes. It has been used as a reagent in aminohydroxylation and allylic amination reactions, a nitrogen source in aziridination reactions of alkenes and alkenes, and deprotection of sulfur groups in sulfur-containing compounds. It has been used as a reagent in the synthesis of factor Xa inhibitors. ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) (0.2% w/v) is also an antimicrobial agent that kills Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Enterococcus cloacae.
    ChloraMine-T hydrate
  • HY-105240
    Delparantag
    		Inhibitor
    Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH.
    Delparantag
  • HY-153836A
    Anivamersen sodium
    		Inhibitor
    Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen sodium
  • HY-18660S
    Ciraparantag-d8 tetrahydrochloride diacetate
    		Inhibitor
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag-d<sub>8</sub> tetrahydrochloride diacetate
  • HY-W854549
    Heparin pentasaccharide
    		Inhibitor
    Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
    Heparin pentasaccharide
  • HY-76409
    Otamixaban hydrochloride
    		Inhibitor 98.50%
    Otamixaban (FXV673) is a potent, selective, rapid-acting, competitive, and reversible fXa inhibitor (Ki=0.5 nM) that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban hydrochloride
  • HY-100652A
    O-Desmethyl apixaban sulfate sodium
    		Inhibitor
    O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM.
    O-Desmethyl apixaban sulfate sodium
  • HY-125856A
    Milvexian TFA
    		Inhibitor
    Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials.
    Milvexian TFA
  • HY-12631
    BMS-654457
    		Inhibitor
    BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively.
    BMS-654457
  • HY-144658
    FXIa-IN-8
    		Inhibitor
    FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
    FXIa-IN-8
Cat. No. Product Name / Synonyms Application Reactivity